Hospital Acquired Pneumonia clinical trials

Explore recruiting hospital acquired pneumonia clinical trials.

Recruiting hospital acquired pneumonia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hospital Acquired Pneumonia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Baricitinib for treating hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international phase II / phase III, randomized, controlled trial - the TREAT-HAP study.

Spain, France, Belgium, Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

Dexamethasone for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international phase III, double-blind, placebo-controlled, randomized trial - the HAP-DEX study

France, Belgium, Greece, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

EaRly impAct theraPy with ceftazidime-avibactam via rapID diagnostics versus standard of care antibiotics and diagnostics in patients with bloodstream infection, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales ("RAPID")

Italy

Therapeutic use (Phase IV) EU CTIS Study details

Effect of early dexamethasone on major complications and all-cause mortality in severe burns

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Use of MULTIplex PCR, procalcitonin and the appearance of sputum to reduce the duration of antibiotic therapy during severe COPD EXAcerbation: a trial controlled, randomized, open, in parallel groups, multicenter (MULTI-EXA)

France

Phase III and phase IV (Integrated) EU CTIS Study details

C3601010: A Phase 2A, 2-Part, Open-Label, Non-Randomized, Multicenter, Single and Multiple Dose Trial to Evaluate Pharmacokinetics, Safety and Tolerability of Aztreonam and Avibactam ± Metronidazole in Neonates and Infants From Birth to Less Than 9 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment

Slovakia, Greece, Bulgaria, Italy, Hungary, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Hospital Acquired Pneumonia trials by city

Hospital Acquired Pneumonia in Toronto Hospital Acquired Pneumonia in Vancouver Hospital Acquired Pneumonia in Montreal Hospital Acquired Pneumonia in Calgary Hospital Acquired Pneumonia in Edmonton Hospital Acquired Pneumonia in Ottawa Hospital Acquired Pneumonia in Winnipeg Hospital Acquired Pneumonia in Quebec City Hospital Acquired Pneumonia in Hamilton Hospital Acquired Pneumonia in Kitchener Hospital Acquired Pneumonia in London Hospital Acquired Pneumonia in Halifax Hospital Acquired Pneumonia in New York Hospital Acquired Pneumonia in Los Angeles Hospital Acquired Pneumonia in Chicago Hospital Acquired Pneumonia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease